Transplantation |

Association Between Pretransplant Statins Therapy and Graft Survival in Lung Transplant Recipients FREE TO VIEW

Kongkiat Chaikriangkrai; Hye Yeon Jhun; Soma Jyothula
Author and Funding Information

Houston Methodist Hospital, Houston, TX

Chest. 2014;146(4_MeetingAbstracts):978A. doi:10.1378/chest.1976580
Text Size: A A A
Published online


SESSION TITLE: Lung Transplantation Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: Statins have been frequently investigated for their immunomodulatory effect in various population. Recently, initiation of statins therapy posttransplant has been shown to have mortality benefit in lung transplant recipients. This study was to examine association between statins use prior to lung transplant and lung allograft survival rate after transplant.

METHODS: Consecutive lung transplant recipients in our facility from January 2009 to June 2012 were retrospectively reviewed. Heart/Lung transplants were excluded. Indication for statins was solely for dyslipidemia management. Clinical variables were compared between patients with and without lung allograft failure determined as all-cause mortality and/or re-transplant. Perioperative events were defined as events that occurred within 30 days after transplant.

RESULTS: The cohort comprised of 324 cases with 58.3% male (189 of 324) and mean age (SD) of 58(13) years. Majority of patients had double lung transplant (62.8%; 203 of 324). Mean (SD) follow up interval was 2.0 (1.2) years. Idiopathic pulmonary fibrosis was leading primary lung pathology (46.9%), followed by COPD (23.1%) and cystic fibrosis (6.5%). The rest was others (23.5%). Baseline cardiovascular diseases and medications were similar between the two groups including coronary artery disease (p 0.233), atrial fibrillation (p 0.501), stroke (p 0.412), hypertension (p 0.460), diabetes (p 0.096), dyslipidemia (p 0.867), aspirin (p 0.487), beta blockers (p 0.922), ACEI (p 0.186) and ARB (p 0.457). Graft failure occurred in 25% (82 of 324) of the cohort (71 death and 12 retransplants). Of those, 27.2% (22 of 82) were perioperative. Kaplan Meier survival analysis showed no statistically significant difference in both overall graft survival (p 0.631) and mortality (p 0.664) in up to 4 years after the transplant.

CONCLUSIONS: Use of statins prior to transplant is not associated with improved allografts survival in lung transplant recipients.

CLINICAL IMPLICATIONS: Use of statins in lung transplant candidates might not improve outcomes after the trasplant.

DISCLOSURE: The following authors have nothing to disclose: Kongkiat Chaikriangkrai, Hye Yeon Jhun, Soma Jyothula

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543